Mindray(SZ:300760) Chang Jiang Shang Bao·2025-07-02 03:53Core Viewpoint - The major shareholder of Mindray Medical, Ever Union, plans to reduce its stake by up to 5 million shares, representing 0.41% of the total share capital, due to personal financial needs [1][3]. Group 1: Shareholder Actions - Ever Union has completed three rounds of share reductions from 2020 to 2023, cashing out approximately 5.055 billion yuan [2][6]. - The latest reduction plan could yield around 1.133 billion yuan if the shares are sold at the closing price of 226.50 yuan per share on July 1 [4]. - Ever Union currently holds 51.48 million shares, accounting for 4.25% of Mindray Medical's total shares [3][6]. Group 2: Company Performance - Mindray Medical's revenue and net profit have significantly declined in 2024, with a year-on-year revenue growth of only 5.14% and a net profit growth of 0.74% [10]. - In the first quarter of 2024, the company reported a year-on-year decline in revenue and net profit of 12.12% and 16.81%, respectively [10]. - The company has experienced consecutive quarters of declining revenue and net profit, which is unusual for its historical performance [10]. Group 3: Historical Context and Growth - Mindray Medical was founded in 1991 and has grown through acquisitions, becoming a leader in the medical device industry [8][9]. - The company went public in the U.S. in 2006 and returned to the A-share market in 2018, expanding its business through strategic acquisitions [9]. - From 2016 to 2023, Mindray's revenue grew from 9.032 billion yuan to 34.932 billion yuan, with net profit increasing from 1.6 billion yuan to 11.582 billion yuan [10].